SEARCH

SEARCH BY CITATION

References

  • 1
    Nagashima Y, Kuroda N, Yao M. Transition of organizational category on renal cancer. Jpn J Clin Oncol 2013; 43: 233242.
  • 2
    Kuroda N, Tanaka A. Recent advances of renal tumor classification. Med Mol Morphol 2013 DOI:10.1007/s00795-013-0033-0.
  • 3
    Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions. A sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003; 27: 750761.
  • 4
    Kuroda N, Mikami S, Pan CC et al. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. Histol Histopathol 2012; 27: 133140.
  • 5
    Macher-Goeppinger S, Roth W, Wagener N et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 2012; 25: 308315.
  • 6
    Argani P, Lae M, Hutchinson B et al. Renal carcinomas with the t(6;11)(p21;q12). Clinicopathologic features and demonstration of the specific Alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA-PCR. Am J Surg Pathol 2005; 29: 230240.
  • 7
    Kuroda N, Tanaka A, Sasaki N et al. Review of renal carcinoma with t(6;11)(p21;q12) with focus on clinical and pathobiological aspects. Histol Histopathol 2013; 28: 685690.
  • 8
    Debelenko LV, Raimondi SC, Daw N et al. Renal cell carcinoma with novel VCL-ALK fusion: New representative ALK-associated tumor spectrum. Mod Pathol 2011; 24: 430442.
  • 9
    Mariño-Enríquez A, Ou WB, Weldon CB, Fletcher JA, Pérez-Atayde AR. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011; 50: 146153.
  • 10
    Sugawara E, Togashi Y, Kuroda N et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012; 118: 44274436.
  • 11
    Sukov WR, Hodge JC, Lohse CM et al. ALK alterations in adult renal cell carcinomas: Frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 2012; 25: 15161525.
  • 12
    Tickoo SK, dePeralta-Venturina MN, Harik LR et al. Spectrum of epithelial neoplasms in end-stage renal disease: An experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 2006; 30: 141153.
  • 13
    Pan CC, Chen YJ, Chang LC, Chang YH, Ho DMT. Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma. Histopathology 2009; 55: 145153.
  • 14
    Bhatnagar R, Alexiev BA. Renal cell carcinoma in end-stage kidneys: A clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma. Int J Surg Pathol 2012; 20: 1928.
  • 15
    Kuroda N, Ohe C, Mikami S et al. Review of acquired cystic disease-associated renal cell carcinoma with focus on pathobiological aspects. Histol Histopathol 2011; 26: 12151218.
  • 16
    Inoue T, Matuura K, Yoshimoto T et al. Genomic profiling of renal cell carcinoma in patients of end-stage renal disease. Cancer Sci 2012; 103: 569575.
  • 17
    Gobbo S, Eble JN, Grignon DJ et al. Clear cell papillary renal cell carcinoma. A distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008; 32: 12391245.
  • 18
    Yang XJ, Zhou M, Hes O et al. Tubulocystic carcinoma of the kidney. Clinicopathologic and molecular genetic characterization. Am J Surg Pathol 2008; 32: 177187.
  • 19
    Zhou M, Yang XJ, Lopez JI et al. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: Implications for pathologic classification. Am J Surg Pathol 2009; 33: 18401849.
  • 20
    Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002; 10: 332338.
  • 21
    Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasm. Clin Lab Med 2005; 25: 247257.
  • 22
    Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Sem Diagn Pathol 2005; 22: 5168.
  • 23
    Troung LD, Shen SS. Immunohisotchemical diagnosis of renal neoplasm. Arch Pathol Lab Med 2011; 135: 92109.
  • 24
    Shen SS, Troung LD, Scarpelli M, Lopez-Beltran A. Role of immunohistochemistry in diagnosing renal neoplasms. When is it really useful? Arch Pathol Lab Med 2012; 136: 410417.
  • 25
    Skinnider B, Folpe AL, Hennigar RA et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue. Potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005; 29: 747754.
  • 26
    Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000; 24: 203210.
  • 27
    Kuehn A, Paner GP, Skinnider BF et al. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: Diagnostic and histogenetic implications. Am J Surg Pathol 2007; 31: 15281533.
  • 28
    Shen SS, Krishna B, Chirala R, Amato RJ, Troung LD. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol 2005; 18: 933940.
  • 29
    Genega EM, Ghbremichael M, Najarian R et al. Carbonic anhydrase IX expression in renal neoplasms. Correlation with tumor type and grade. Am J Clin Pathol 2010; 134: 873879.
  • 30
    Williamson SR, Halat S, Eble JN et al. Multilocular cystic renal cell carcinoma. Similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. Am J Surg Pathol 2012; 36: 14251433.
  • 31
    Kuroda N, Ohe C, Mikami S et al. Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2012; 27: 969974.
  • 32
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18: 487494.
  • 33
    Szponar A, Yusenko MV, Kuiper R, van Kessel AG, Kovacs G. Genomic profiling of papillary renal cell tumours identifies small regions of DNA alterations: A possible role of HNF1B in tumour development. Histopathology 2011; 58: 934943.
  • 34
    Tretiakova MS, Sahoo S, Takahashi M et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 2004; 28: 6976.
  • 35
    Paner GP, Srigley JR, Radhakrishnan A et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney. Significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol 2006; 30: 1319.
  • 36
    Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel B, Sunani M. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: A tissue microarray study. Mod Pathol 2005; 18: 535540.
  • 37
    Molinié V, Balaton A, Rotman S et al. Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol 2006; 37: 698703.
  • 38
    Lagner C, Ratschek M, Rehak P, Schips L, Zigueuner R. CD10 expression is a diagnostic and prognostic marker in renal malignancies. Histopathology 2004; 45: 460467.
  • 39
    Olgac S, Hutchinson B, Tickoo SK, Reuter VE. Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol 2006; 19: 218224.
  • 40
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of chromophobe renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18: 165171.
  • 41
    Martignoni G, Pea M, Chillossi M et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol 2001; 14: 760767.
  • 42
    Abrahams NA, MacLennan GT, Khoury JD et al. Chromophobe renal cell carcinoma: A comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology 2004; 45: 593602.
  • 43
    Yusenko MV, Kovacs G. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma. Histopathology 2009; 55: 687695.
  • 44
    Pan CC, Chen PCH, Ho DMT. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: An immunohistochemical analysis of 328 cases. Histopathology 2004; 45: 452459.
  • 45
    Al-Ahmadie HA, Alden D, Fine SW et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: An ex vivo study. Am J Surg Pathol 2011; 35: 949961.
  • 46
    Ohe C, Kuroda N, Takasu K et al. Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen, and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma. Med Mol Morphol 2012; 45: 98104.
  • 47
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2002; 17: 13291334.
  • 48
    Albadine R, Schultz L, Illei P et al. PAX8(+)/p63(-) immunostaining pattern in renal collecting duct carcinoma (CDC), A useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol 2010; 34: 965969.
  • 49
    Kuroda N, Toi M, Hiroi M, Shuin T, Enzan H. Review of mucinous tubular and spindle-cell carcinoma of the kidney with a focus on clinical and pathobiological aspects. Histol Histopathol 2005; 20: 221224.
  • 50
    Kuroda N, Toi M, Hiroi M, Shuin T, Enzan H. Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18: 935942.
  • 51
    Carvalho JC, Wasco MJ, Kinju LP, Thomas DG, Shah RB. Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C-kit(CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics. Histopathology 2011; 58: 169179.
  • 52
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of metanephric adenoma of the kidney with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18: 253257.
  • 53
    Ozcan A, de la Roza G, Ro JY, Shen SS, Troung LD. PAX2 and PAX8 expression in primary and metastatic renal tumors. A comprehensive comparison. Arch Pathol Lab Med 2012; 136: 15411551.
  • 54
    Muir TE, Cheville JC, Lager DJ. Metanephric adenoma, nephrogenic rests, and Wilms’ tumor. A histologic and immunophenotypic comparison. Am J Surg Pathol 2001; 25: 12901296.
  • 55
    Jung SJ, Chung JI, Park SH, Ayala AG, Ro JY. Thyroid follicular carcinoma-like tumor of kidney: A case report with morphologic, immunohistochemical and genetic analysis. Am J Surg Pathol 2006; 30: 411415.
  • 56
    Amin MB, Gupta R, Hes O et al. Primary thyroid-like follicular carcinoma of the kidney: Report of 6 cases with a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol 2009; 33: 393400.
  • 57
    Insabato L, Ben-Dor D, Galliani CA, Lastilla G, Bisceglia M. Primary thyroid and thyroid-like follicular carcinoma of the kidney versus solitary metastatic carcinoma of the thyroid: A vexing issue. Virchows Arch 2009; 454: 717718.
  • 58
    Dhillon J, Tannir NM, Matin SF et al. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol 2011; 42: 146150.